

# Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult

Ozlem O. Karakus <sup>1</sup>, Noureldien H. E. Darwish <sup>1,2</sup>, Thangirala Sudha <sup>1</sup>, Taher A. Salaheldin <sup>1</sup>, Kazutoshi Fujioka <sup>1</sup>, P. C. Taylor Dickinson <sup>3</sup>, Brian Weil <sup>4,5</sup> and Shaker A. Mousa <sup>1,\*</sup>

<sup>1</sup> The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA; Ozlem.Karakus@acphs.edu (O.O.K.); noureldien.darwish@acphs.edu (N.H.E.D.); sudha.thangirala@acphs.edu (T.S.); taher.salaheldin@acphs.edu (T.A.S.); Kazutoshi.Fujioka@acphs.edu (K.F.)

<sup>2</sup> Clinical Pathology (Hematology Section), Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt

<sup>3</sup> Pro-Al Medico Technologies Inc., Suffern, NY 10901, USA; dickinsonpct@gmail.com

<sup>4</sup> Departments of Physiology & Biophysics, School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA; bweil@buffalo.edu

<sup>5</sup> VA WNY Healthcare System, Buffalo, NY 14215, USA

## **\*Correspondence:**

Shaker A. Mousa  
The Pharmaceutical Research Institute  
Albany College of Pharmacy and Health Sciences  
1 Discovery Drive, Rensselaer, NY 12144  
Phone: (518) 694-7397  
Fax: (518) 694-7567  
Email: shaker.mousa@acphs.edu

## **Table of Contents**

**Figure S1.**  $^1\text{H}$ -NMR spectrum of compound 2

**Figure S2.**  $^{13}\text{C}$ -NMR spectrum of compound 2

**Figure S3.**  $^1\text{H}$  -NMR spectrum of compound 3

**Figure S4.**  $^{13}\text{C}$ -NMR spectrum of compound 3

**Figure S5.**  $^1\text{H}$  -NMR spectrum of compound 4

**Figure S6.**  $^{13}\text{C}$  -NMR spectrum of compound 4


**Figure S7.**  $^1\text{H}$  -NMR spectrum of compound 5

**Figure S8.**  $^{13}\text{C}$  -NMR spectrum of compound 5


**Figure S9.**  $^1\text{H}$  -NMR spectrum of compound 7

**Figure S10.** Characterization of prepared nano capsules (a) particle size distribution of void nanoparticles showing average size of 150 nm; (b) particle size of PLGA-T3 NPs; (c) particle size of PLGA-T3/PCr NPs


**Figure S11.** Calibration curve of T3




**Figure S1:** <sup>1</sup>H-NMR Spectrum of compound 2




**Figure S2:** <sup>13</sup>C-NMR Spectrum of compound 2




**Figure S3:** <sup>1</sup>H-NMR Spectrum of compound 3




**Figure S4:** <sup>13</sup>C-NMR Spectrum of compound 3




**Figure S5:** <sup>1</sup>H-NMR Spectrum of compound 4




**Figure S6:** <sup>13</sup>C-NMR Spectrum of compound 4




**Figure S7:** <sup>1</sup>H-NMR Spectrum of compound 5



**Figure S8:** <sup>13</sup>C-NMR Spectrum of compound 5



**Figure S9:**  $^1\text{H}$ -NMR Spectrum of compound 7



**Figure S10.** Characterization of prepared nano capsules (a) particle size distribution of void nanoparticles showing average size of 150 nm (250?); (b) particle size of PLGA-T3 NPs, size 175; (c) particle size of PLGA-T3/PCr NPs, size 187.




Figure S11. Calibration curve of T3